久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Basic Info

  • Grade: pharmaceutical grade

    Factory Location: Shanghai

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Secatinib is an oral biologic that is a selective inhibitor of wild-type, mutant, and fusion products. It involves rearrangement of the oncogene receptor tyrosine kinase during transfection (RET) and has potential anti-tumor activity. After oral administration, secatinib can selectively bind to wild-type RET as well as various RET mutants and fusion products containing RET, and use them as targets. This will lead to inhibition of the growth of tumor cells exhibiting increased RET activity. In addition, secatinib can also target, bind, and inhibit vascular endothelial growth factor receptors 1 (VEGFR1) and 3 (VEGFR3), as well as fibroblast growth factor receptors 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). Overexpression, activation mutations, and fusion of RET lead to upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; The imbalance of RET activity plays a crucial role in the development and progression of these cancers.
Send your message to this supplier
  • From:
  • To:
    Shanghai Hope-chem Co.,Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    -?Supports?jpg,?jpeg,?png,
    ?gif,?pdf,?doc,?docx,
    ?xls,?xlsx,?txt,?rar?and?zip
    -?Max?upload?3?files;
    ?Max??total?size:?3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service